You have 9 free searches left this month | for more free features.

Metastatic head and neck cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Head Neck Cancer, Intratumoral Injection Trial in Chicago (RiMO-301)

Recruiting
  • Head Neck Cancer
  • Intratumoral Injection
  • Chicago, Illinois
    University of Illinois at Chicago
Apr 28, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma Trial in Portland (GB1211, Pembrolizumab, Placebo)

Not yet recruiting
  • Metastatic Melanoma
  • Head and Neck Squamous Cell Carcinoma
  • Portland, Oregon
    Providence Portland Medical Center
Jun 19, 2023

Head Neck Cancer, Head and Neck Squamous Cell Carcinoma Trial (ALE.C04, Pembrolizumab)

Not yet recruiting
  • Head and Neck Cancer
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Sep 19, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Prognostic Immune Biomarkers in HNSCC

Completed
  • Head and Neck Cancer
  • Squamous Cell Carcinoma
  • Tumour immunoprofile evaluation
  • Ostrava, Moravian-Silesian Region, Czechia
    University Hospital Ostrava
Jul 3, 2023

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Panitumumab
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 16, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • (no location specified)
Jun 9, 2023

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Head Neck Cancer Trial in Charleston (Pembrolizumab, Clopidogrel, acetylsalicylic acid)

Recruiting
  • Head and Neck Cancer
  • Charleston, South Carolina
    Medical University of South Carolina
Dec 22, 2022

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck Trial

Not yet recruiting
  • Head and Neck Cancer
  • +4 more
  • Ozuriftamab Vedotin
  • PD-1 inhibitor
  • (no location specified)
Jul 28, 2022

Cancer Head Neck, Metastatic Cancer, Metastatic Lung Cancer Trial in New Haven (adnectin 18F-BMS-986192 Head and Neck Cancer,

Not yet recruiting
  • Cancer Head Neck
  • +2 more
  • adnectin 18F-BMS-986192 Head and Neck Cancer
  • adnectin 18F-BMS-986192 Brain Metastases
  • New Haven, Connecticut
    Yale University PET Center
Oct 10, 2022

Recurrent Head Neck Cancer, Metastatic Head Neck Cancer Trial (Pembrolizumab, Cisplatin, Carboplatin)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • Metastatic Head and Neck Cancer
  • Pembrolizumab
  • +4 more
  • (no location specified)
Aug 18, 2022

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Head Neck Cancer, Metastatic Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma Trial in Winston-Salem (Pembrolizumab,

Recruiting
  • Head Neck Cancer
  • +5 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Health Sciences
Aug 8, 2022

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial in Houston (other,

Recruiting
  • Metastatic Head and Neck Squamous Cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Hafnium Oxide-containing Nanoparticles NBTXR3
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer

Active, not recruiting
  • Head and Neck Squamous Cell Cancer
  • +2 more
  • Miami, Florida
  • +8 more
Dec 2, 2022

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin Trial in Australia, United States (TH-4000)

Terminated
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • TH-4000 (Tarloxotinib)
  • Los Angeles, California
  • +9 more
Jan 9, 2023